Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
44
CVKD Quote, Financials, Valuation and Earnings
Last price:
$9.90
Seasonality move
:
23.77%
Day range:
$9.84 - $11.04
52-week range:
$8.12 - $22.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.73x
Volume:
38.4K
Avg. volume:
26.2K
1-year change:
-23.86%
Market cap:
$21.1M
Revenue:
--
EPS (TTM):
-$8.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CVKD
Cadrenal Therapeutics, Inc.
|
-- | -$1.55 | -- | -55.93% | $35.67 |
|
ABT
Abbott Laboratories
|
$11.4B | $1.30 | 7.5% | -71.7% | $144.43 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -7.04% | -11.5% | $3.75 |
|
PTCT
PTC Therapeutics, Inc.
|
$175.5M | -$1.11 | 14.46% | -47.27% | $81.86 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CVKD
Cadrenal Therapeutics, Inc.
|
$10.18 | $35.67 | $21.1M | -- | $0.00 | 0% | -- |
|
ABT
Abbott Laboratories
|
$125.08 | $144.43 | $217.5B | 15.69x | $0.59 | 1.89% | 4.99x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$6.45 | $42.50 | $19.6M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.75 | $27.7M | -- | $0.00 | 0% | 22.36x |
|
PTCT
PTC Therapeutics, Inc.
|
$77.26 | $81.86 | $6.2B | 9.03x | $0.00 | 0% | 3.57x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CVKD
Cadrenal Therapeutics, Inc.
|
-- | 0.526 | -- | 2.85x |
|
ABT
Abbott Laboratories
|
20.25% | 0.426 | 5.99% | 1.12x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
PTCT
PTC Therapeutics, Inc.
|
161.23% | 0.296 | 8.36% | 2.20x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CVKD
Cadrenal Therapeutics, Inc.
|
-$400 | -$2.7M | -299.69% | -299.72% | -- | -$2.4M |
|
ABT
Abbott Laboratories
|
$5.9B | $2.2B | 22.49% | 29.06% | 19.03% | $2.3B |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
PTCT
PTC Therapeutics, Inc.
|
$187.7M | $3.5M | -382.54% | -- | 1.65% | -$322.5M |
Cadrenal Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CVKD or ABT?
Abbott Laboratories has a net margin of -- compared to Cadrenal Therapeutics, Inc.'s net margin of 14.07%. Cadrenal Therapeutics, Inc.'s return on equity of -299.72% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital CVKDCadrenal Therapeutics, Inc.-- -$1.31 $2.7M ABTAbbott Laboratories52.05% $0.91 $64.2B -
What do Analysts Say About CVKD or ABT?
Cadrenal Therapeutics, Inc. has a consensus price target of $35.67, signalling upside risk potential of 250.36%. On the other hand Abbott Laboratories has an analysts' consensus of $144.43 which suggests that it could grow by 15.47%. Given that Cadrenal Therapeutics, Inc. has higher upside potential than Abbott Laboratories, analysts believe Cadrenal Therapeutics, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings CVKDCadrenal Therapeutics, Inc.1 0 0 ABTAbbott Laboratories15 7 0 -
Is CVKD or ABT More Risky?
Cadrenal Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.716, suggesting its less volatile than the S&P 500 by 28.412%.
-
Which is a Better Dividend Stock CVKD or ABT?
Cadrenal Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 1.89% to investors and pays a quarterly dividend of $0.59 per share. Cadrenal Therapeutics, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 29.33% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CVKD or ABT?
Cadrenal Therapeutics, Inc. quarterly revenues are --, which are smaller than Abbott Laboratories quarterly revenues of $11.4B. Cadrenal Therapeutics, Inc.'s net income of -$2.7M is lower than Abbott Laboratories's net income of $1.6B. Notably, Cadrenal Therapeutics, Inc.'s price-to-earnings ratio is -- while Abbott Laboratories's PE ratio is 15.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cadrenal Therapeutics, Inc. is -- versus 4.99x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVKDCadrenal Therapeutics, Inc.-- -- -- -$2.7M ABTAbbott Laboratories4.99x 15.69x $11.4B $1.6B
-
Which has Higher Returns CVKD or AIM?
AIM ImmunoTech has a net margin of -- compared to Cadrenal Therapeutics, Inc.'s net margin of -10571.43%. Cadrenal Therapeutics, Inc.'s return on equity of -299.72% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital CVKDCadrenal Therapeutics, Inc.-- -$1.31 $2.7M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About CVKD or AIM?
Cadrenal Therapeutics, Inc. has a consensus price target of $35.67, signalling upside risk potential of 250.36%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Cadrenal Therapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than Cadrenal Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVKDCadrenal Therapeutics, Inc.1 0 0 AIMAIM ImmunoTech1 0 0 -
Is CVKD or AIM More Risky?
Cadrenal Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock CVKD or AIM?
Cadrenal Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cadrenal Therapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVKD or AIM?
Cadrenal Therapeutics, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. Cadrenal Therapeutics, Inc.'s net income of -$2.7M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Cadrenal Therapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cadrenal Therapeutics, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVKDCadrenal Therapeutics, Inc.-- -- -- -$2.7M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns CVKD or CVM?
CEL-SCI Corp. has a net margin of -- compared to Cadrenal Therapeutics, Inc.'s net margin of --. Cadrenal Therapeutics, Inc.'s return on equity of -299.72% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital CVKDCadrenal Therapeutics, Inc.-- -$1.31 $2.7M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About CVKD or CVM?
Cadrenal Therapeutics, Inc. has a consensus price target of $35.67, signalling upside risk potential of 250.36%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 558.92%. Given that CEL-SCI Corp. has higher upside potential than Cadrenal Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Cadrenal Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVKDCadrenal Therapeutics, Inc.1 0 0 CVMCEL-SCI Corp.1 0 0 -
Is CVKD or CVM More Risky?
Cadrenal Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock CVKD or CVM?
Cadrenal Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cadrenal Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVKD or CVM?
Cadrenal Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Cadrenal Therapeutics, Inc.'s net income of -$2.7M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Cadrenal Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cadrenal Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVKDCadrenal Therapeutics, Inc.-- -- -- -$2.7M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns CVKD or IGC?
IGC Pharma, Inc. has a net margin of -- compared to Cadrenal Therapeutics, Inc.'s net margin of -953.4%. Cadrenal Therapeutics, Inc.'s return on equity of -299.72% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital CVKDCadrenal Therapeutics, Inc.-- -$1.31 $2.7M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About CVKD or IGC?
Cadrenal Therapeutics, Inc. has a consensus price target of $35.67, signalling upside risk potential of 250.36%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.75 which suggests that it could grow by 1158.81%. Given that IGC Pharma, Inc. has higher upside potential than Cadrenal Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Cadrenal Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVKDCadrenal Therapeutics, Inc.1 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is CVKD or IGC More Risky?
Cadrenal Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock CVKD or IGC?
Cadrenal Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cadrenal Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVKD or IGC?
Cadrenal Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Cadrenal Therapeutics, Inc.'s net income of -$2.7M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Cadrenal Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cadrenal Therapeutics, Inc. is -- versus 22.36x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVKDCadrenal Therapeutics, Inc.-- -- -- -$2.7M IGCIGC Pharma, Inc.22.36x -- $191K -$1.8M
-
Which has Higher Returns CVKD or PTCT?
PTC Therapeutics, Inc. has a net margin of -- compared to Cadrenal Therapeutics, Inc.'s net margin of 7.53%. Cadrenal Therapeutics, Inc.'s return on equity of -299.72% beat PTC Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CVKDCadrenal Therapeutics, Inc.-- -$1.31 $2.7M PTCTPTC Therapeutics, Inc.88.95% $0.20 $254.4M -
What do Analysts Say About CVKD or PTCT?
Cadrenal Therapeutics, Inc. has a consensus price target of $35.67, signalling upside risk potential of 250.36%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $81.86 which suggests that it could grow by 5.96%. Given that Cadrenal Therapeutics, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Cadrenal Therapeutics, Inc. is more attractive than PTC Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CVKDCadrenal Therapeutics, Inc.1 0 0 PTCTPTC Therapeutics, Inc.7 5 1 -
Is CVKD or PTCT More Risky?
Cadrenal Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.999%.
-
Which is a Better Dividend Stock CVKD or PTCT?
Cadrenal Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cadrenal Therapeutics, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CVKD or PTCT?
Cadrenal Therapeutics, Inc. quarterly revenues are --, which are smaller than PTC Therapeutics, Inc. quarterly revenues of $211M. Cadrenal Therapeutics, Inc.'s net income of -$2.7M is lower than PTC Therapeutics, Inc.'s net income of $15.9M. Notably, Cadrenal Therapeutics, Inc.'s price-to-earnings ratio is -- while PTC Therapeutics, Inc.'s PE ratio is 9.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cadrenal Therapeutics, Inc. is -- versus 3.57x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CVKDCadrenal Therapeutics, Inc.-- -- -- -$2.7M PTCTPTC Therapeutics, Inc.3.57x 9.03x $211M $15.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
72
KYMR alert for Dec 8
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
